# Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-

> **NCT06895577** · PHASE2 · WITHDRAWN · sponsor: **Sun Yat-sen University**

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** neoadjuvant SCRT followed by Sintilimab plus CAPOX

## Key facts

- **NCT ID:** NCT06895577
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to errors in the previously submitted modification, we request to withdraw it and will submit a corrected update shortly.
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06895577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06895577, "Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06895577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*